These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 7507539)

  • 61. Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.
    Belz GG; Kirch W; Kleinbloesem CH
    Clin Pharmacokinet; 1988 Nov; 15(5):295-318. PubMed ID: 2849518
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Rethinking the renin-angiotensin system and its role in cardiovascular regulation.
    Pagliaro P; Penna C
    Cardiovasc Drugs Ther; 2005 Jan; 19(1):77-87. PubMed ID: 15883759
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Angiotensin-Converting Enzymes (ACE and ACE2) as Potential Targets for Malignant Epithelial Neoplasia: Review and Bioinformatics Analyses Focused in Oral Squamous Cell Carcinoma.
    de Carvalho Fraga CA; Farias LC; Jones KM; Batista de Paula AM; Guimaraes ALS
    Protein Pept Lett; 2017 Nov; 24(9):784-792. PubMed ID: 28814250
    [TBL] [Abstract][Full Text] [Related]  

  • 64. ACE inhibitors and tissue binding.
    Lancet; 1990 Sep; 336(8717):718-20. PubMed ID: 1975896
    [No Abstract]   [Full Text] [Related]  

  • 65. Differences in structure of angiotensin-converting enzyme inhibitors might predict differences in action.
    Herman AG
    Am J Cardiol; 1992 Oct; 70(10):102C-108C. PubMed ID: 1329464
    [TBL] [Abstract][Full Text] [Related]  

  • 66. From kinetics to dynamics: are there differences between ACE inhibitors?
    Reid JL
    Eur Heart J; 1997 Nov; 18 Suppl E():E14-8. PubMed ID: 9402467
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Structure of human ACE gives new insights into inhibitor binding and design.
    Brew K
    Trends Pharmacol Sci; 2003 Aug; 24(8):391-4. PubMed ID: 12915047
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Novel domain-selective ACE-inhibiting activity of synthetic growth hormone secretagogues.
    Torsello A; Bresciani E; Ravelli M; Rizzi L; Bulgarelli I; Ricci G; Ghiazza B; Del Puppo M; Mainini V; Omeljaniuk RJ; Tamiazzo L; Mancia G; Magni F; Locatelli V
    Pharmacol Res; 2012 Oct; 66(4):317-24. PubMed ID: 22732396
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Biochemistry and cell biology of angiotensin-converting enzyme and converting enzyme inhibitors.
    Berecek KH; Zhang L
    Adv Exp Med Biol; 1995; 377():141-68. PubMed ID: 7484420
    [No Abstract]   [Full Text] [Related]  

  • 70. Pharmacologic profile of trandolapril, a new angiotensin-converting enzyme inhibitor.
    Conen H; Brunner HR
    Am Heart J; 1993 May; 125(5 Pt 2):1525-31. PubMed ID: 8480624
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.
    MacFadyen RJ; Lees KR; Reid JL
    Br J Clin Pharmacol; 1991 Jan; 31(1):1-13. PubMed ID: 1849731
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Demonstration of in vivo effects of ACE inhibitors by the use of autoregressive modelling.
    Wada T; Aoyagi T
    Adv Exp Med Biol; 1989; 247A():191-5. PubMed ID: 2557740
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Angiotensin I converting enzyme--properties, functions and methods of analysis].
    Siems WE; Halle W
    Pharmazie; 1982 Aug; 37(8):539-44. PubMed ID: 6292961
    [No Abstract]   [Full Text] [Related]  

  • 74. The tissue renin-angiotensin system and its functional role.
    Johnston CI; Burrell LM; Perich R; Jandeleit K; Jackson B
    Clin Exp Pharmacol Physiol Suppl; 1992; 19():1-5. PubMed ID: 1327595
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Design and synthesis of 3-(3-((9H-carbazol-4-yl)oxy)-2-hydroxypropyl)-2-phenylquinazolin-4(3H)-one derivatives to induce ACE inhibitory activity.
    Venkatesh R; Kasaboina S; Gaikwad HK; Janardhan S; Bantu R; Nagarapu L; Sastry GN; Banerjee SK
    Eur J Med Chem; 2015; 96():22-9. PubMed ID: 25874328
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Properties and distribution of angiotensin I converting enzyme.
    Igić R; Behnia R
    Curr Pharm Des; 2003; 9(9):697-706. PubMed ID: 12570787
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of ACE-inhibition on regional circulation in congestive heart failure.
    Swedberg K
    Acta Med Scand Suppl; 1986; 707():91-3. PubMed ID: 3017058
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Manipulating the renin-angiotensin system: more than we bargained for?
    Gardner DG
    Am J Med; 2002 Feb; 112(2):152-3. PubMed ID: 11835956
    [No Abstract]   [Full Text] [Related]  

  • 79. Developmental biology of angiotensin-converting enzyme.
    Yosipiv IV; El-Dahr SS
    Pediatr Nephrol; 1998 Jan; 12(1):72-9. PubMed ID: 9502575
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Differential effects of ACE inhibiting drugs: evidence for concentration-, dose-, and agent-dependent responses.
    MacFadyen RJ; Meredith PA; Elliott HL
    Clin Pharmacol Ther; 1993 Jun; 53(6):622-9. PubMed ID: 8513653
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.